Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 (Evusheld) Dose-Ranging for COVID-19 PrEP in Immunocompromised
NCT05375760Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tixagevimab + cilgavimab in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Jun 2022; status: terminated.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05375760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05375760.